DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 21976/S-36
NDA 202895/S-13

SUPPLEMENT APPROVAL

Janssen Product, L.P.
Attention: Karen Gerry, B.Sc.
Manager, Global Regulatory Affairs
1125 Trenton-Harbourton Road
Titusville, NJ 08560

Dear Ms. Gerry:

Please refer to your Supplemental New Drug Applications (sNDA) dated March 14, 2014, received March 14, 2014, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Prezista® (darunavir) tablet, 75 mg, 150 mg, 600 mg, 800 mg and Prezista® (darunavir) oral suspension, 100 mg/mL.

We acknowledge receipt of your amendments dated March 27, 2014, April 23, 2014, September 4, 2014, September 24, 2014, February 23, 2015, March 17, 2015, March 23, 2015, March 31, 2015, and April 6, 2015.

These Prior Approval supplemental new drug applications propose the following changes:

1. To update the CONTRAINDICATIONS section of labeling and, if applicable, the Patient Information (Who should not take Prezista section) with information regarding the following newly added medications: colchicine, dronedarone, and ranolazine and to modify the information for pimozide.

2. To update the DRUG INTERACTIONS, *Potential for PREZISTA/ritonavir to Affect Other Drugs and Potential for Other Drugs to Affect Darunavir* sections, and the CLINICAL PHARMACOLOGY, *Pharmacokinetics, Drug Interactions* subsection with P-gp information.

3. To update DRUG INTERACTIONS, Table 11, *Established and Other Potentially Significant Drug Interactions* subsection of the labeling and, if applicable, the Patient Information (What should I tell my doctor before I take Prezista? section) with newly added medications or to modify information for existing medications in the following classes:

Drug Class
Antiarrhythmics
Antibacterial
Anticoagulant
Antidepressant
Antifungals
Antigout
Antimycobacterial
Antineoplastics
Antipsychotics/Neuroleptics
β-Blockers
Calcium Channel Blockers
Corticosteroid
Hepatitis C Virus (HCV) Direct-Acting Agents: NS3-4A protease inhibitors
HMG-CoA Reductase Inhibitors
Immunosupressants
Narcotic Analgesic/Treatment of Opiod Dependance
PDE-5 inhibitors
Sedative/Hypnotics

4. To update the Drug Interactions, *7.3 Established and Other Potentially Significant Drug Interactions* section with information for pitavastatin, acid modifying medications, and HIV integrase strand transfer inhibitors.

5. To update Table 14 (Drug Interactions: Pharmacokinetic Parameters for Darunavir in the Presence of Co-administered Drugs) and Table 15 (Drug Interactions: Pharmacokinetics Parameters for Co-administered Drugs in the Presence of Darunavir/Ritonavir) with simeprevir drug-drug interaction information.

APPROVAL & LABELING

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the

patient package insert, Medication Guide), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)
5901-B Ammendale Road
Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf. Information and Instructions for completing the form can be found at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above or by fax to 301-847-8444.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Linda C. Onaga, MPH, Senior Regulatory Project Manager, at (301) 796-0759 or the Division mainline at (301) 796-1500.

Sincerely,

{See appended electronic signature page}

Debra Birnkrant, MD
Director
Division of Antiviral Products
Office of Antimicrobial Products
Center for Drug Evaluation Research

ENCLOSURE(S):
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

POONAM MISHRA
05/27/2015